An interventional study of iCBTI-based EMI and Education-based EMI in Stroke, Insomnia and Depressive Symptoms, sponsored by The University of Hong Kong. Recruiting at 5 sites in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-30.
Sponsored by The University of Hong Kong · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Stroke by The University of Hong Kong — 4 open to participants now, 5 under way, none of them phase 3. Stroke · The University of Hong Kong.
Among the 18 studies in Stroke by The University of Hong Kong, this one is the 6th largest by planned enrollment of the 15 interventional ones that give a count, is one of 5 that started in 2023, is one of 14 with no phase, and was the 16th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →4 of the 18 studies in Stroke by The University of Hong Kong are open now, in 2 countries. Recruiting first, the newest first:
The University of Hong Kong · Sites in Hong Kong
Ages 18+
The University of Hong Kong · Sites in Hong Kong
Ages 50+
The University of Hong Kong · Sites in China
Ages 18–100 · Healthy volunteers
By country, each count listing its studies:
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 5 started in 2023.
This study's planned enrollment of 138 is above the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 102 across the 15 interventional studies, 650 across the 3 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
The University of Hong Kong is the lead sponsor of 1,295 studies on the registry; 351 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
1 of the studies in Stroke by The University of Hong Kong that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05300997The University of Hong KongTranslational Immunodiagnostics in Stroke (TrImS) | 2027-08-31 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in Stroke by The University of Hong Kong, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The proposed trial aims to assess the effectiveness of Cognitive-behavioural therapy for insomnia (CBT-I) based ecological momentary intervention (EMI) for reducing insomnia symptoms among stroke caregivers.
Existing studies reported that 40-95% of family caregivers had clinically significant insomnia symptoms including reduced total sleep duration, prolonged sleep onset latency, frequent night awakenings, and poor sleep efficiency and quality.
Cognitive-behavioural therapy for insomnia (CBT-I) has shown a large effect in reducing insomnia among adults. Innovative and interactive technologies, such as Internet-delivered CBT-I (iCBT-T), have therefore been incorporated into CBT-I, which was identified to have similar effects to that of traditional CBT-I.
In the proposed trial, screened stroke caregivers will be recruited from community centres, rehabilitation centres, and tertiary hospitals in HK. The intervention group will receive CBTI-based EMI through instant messaging applications as personalised and real-time psychological support led by nurses for 3 months. The control group will only receive stroke and brief sleep hygiene education with chat-based support on the topics.The primary outcomes are Sleep Condition Indicator (SCI) and Insomnia Severity Index (ISI) scores. Secondary outcomes will include sleep quality, depressive symptoms, anxiety symptoms, caregiver's burden, quality of life, and et al. A post-trial qualitative study will be conducted to understand the participants' experience of and compliance with the EMI.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Receiving CBT-I based EMI messages.
Behavioral: iCBTI-based EMI
Receiving education-based EMI messages.
Behavioral: Education-based EMI
Including brief iCBT-I for sleep support, stroke care education, and nurse-led real-time chat-based support messages, which were delivered according to participants' preferences (e.g., time and frequency).
Stroke and brief sleep hygiene education with chat-based support on the topics.
Sleep Condition Indicator (SCI)
An eight-item rating scale that was developed to screen for insomnia disorder based on DSM-5 criteria. Possible total score ranges from 0 to 32, with higher values indicative of better sleep.
Time frame: 24 weeks
Insomnia Severity Index (ISI)
A 7-item scale with scoring ranging from 0-28, a higher score indicate more severe insomnia symptoms
Time frame: 24 weeks
Sleep quality (Pittsburgh Sleep Quality Index [PSQI])
A 19-item scale ranging from 0 to 21 with the higher total score (referred to as global score) indicating worse sleep quality
Time frame: 24 weeks
Depressive symptoms (Patient Health Questionnaire-9 [PHQ-9]):
A 9-item scale with score ranging from 0 to 27, higher scores indicate higher severity of depressive symptom
Time frame: 24 weeks
Anxiety symptoms (Generalized Anxiety Disorder-7 [GAD-7])
A 7-item scale with score ranging from 0 to 21, higher scores indicate higher severity of anxiety symptom
Time frame: 24 weeks
Caregiver's burden (Zarit Burden Interview [ZBI-4])
A 4-item scale with score ranging from 0 to 16, higher scores indicate higher severity of caregiving burden
Time frame: 24 weeks
Quality of life (EuroQol 5-dimension 5-level questionnaire [EQ-5D-5L])
The EQ-5D-5L assesses five health dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, each rated on five levels of severity, with scores ranging from -0.864 to 1, where higher scores indicate better quality of life. Additionally, it includes a visual analogue scale (VAS), ranging from 0 (the worst health imaginable) to 100 (the best health imaginable).
Time frame: 24 weeks
Positive experiences from caregiving (Positive Aspect of Caregiving [PAC])
An 11-item scale with scores ranging from 0 to 44. A higher score indicates a more positive caregiving experience.
Time frame: 24 weeks
Caregiving self-efficacy (Caregiving Self-Efficacy Scale [CSES-8])
An 8-item scale with scores ranging from 1 to 10, with higher scores indicating higher self-efficacy.
Time frame: 24 weeks
Sleep parameters (Consensus Sleep Diary Core Version)
The Consensus Sleep Diary Core Version will be used to collect sleep parameters (e.g., sleep efficiency and total sleep time).
Time frame: 24 weeks
Dysfunctional Beliefs and attitudes about Sleep (Dysfunctional Beliefs and attitudes about Sleep [DBAS])
A 16-item scale with scores ranging from 0 to 160, with higher scores indicating greater dysfunctional beliefs about sleep.
Time frame: 24 weeks
Sleep hygiene statue (Sleep Hygiene Index [SHI])
A 13-item scale with ratings from 0 to 52, where higher scores indicate poorer sleep hygiene status.
Time frame: 24 weeks
Sleep-related behavior (Chinese short-form of the sleep-related behavior questionnaire [SRBQ-SF])
A 23-item scale with scores ranging from 0 to 92. A higher score indicates more sleep-related safety behaviors.
Time frame: 24 weeks
State of sleep effort (Glasgow Sleep Effort Scale [GSES])
A 7-item scale with scores ranging from 0 to 14, where higher scores indicate greater effort to sleep over the past week.
Time frame: 24 weeks
Sleep-related quality of life (Glasgow Sleep Impact Index [GSII])
The primary measureable outcomes for the GSII reflect VAS scores (0-100; with lower scores reflecting negative impact) for each of the three specified ranks, capturing impairment in the past two weeks. GSII reflect VAS scores (0-100; with lower scores reflecting negative impact) for each of the three
Time frame: 24 weeks
Feedback on iCBT-I intervention
Feedback on the sleep support programme will be collected, focusing on various aspects such as perceived usefulness and willingness to recommend the program. Each aspect will be evaluated using a 5-point Likert scale, where higher scores indicate more positive evaluations.
Time frame: 24 weeks
Adverse events
Feedback on adverse events related to the iCBT-I intervention, such as fatigue, will be collected.
Time frame: 24 weeks
Started Dec 2023 (actual). Primary completion is estimated for Dec 2024, 12 months after the start.
Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 12 months is below that.
Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.